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Summary The inability to assess the extent of tumour damage immediately following treatment is a major
clinical obstacle to improving the management of cancer patients. Normally, the effectiveness ofchemotherapy
or radiation therapy cannot be determined for at least several weeks after treatment. We studied the increase
in mRNA of the growth arrest and DNA damage-inducible gene GADD153 in human 2008 ovarian carcinoma
cells in vitro and in vivo to determine whether treatment-induced increases in the level of GADD153 mRNA
could be used as a marker of the extent of tumour damage. GADD153 mRNA was increased in a transient,
dose-dependent manner by cisplatin (DDP) when the tumour cells were grown both in vitro and as tumour
xenografts in nude mice. The magnitude of induction of GADD153 mRNA did not vary significantly between
different 2008 xenografts treated with equal doses of DDP, and GADD153 mRNA induction correlated with
the degree of in vitro cytotoxicity for two different schedules of drug exposure. DDP increased GADD153
mRNA levels in melanoma and head and neck xenograft models as well. We conclude that the increase in
GADD153 mRNA can be used to detect tumour injury at time points as short as 24 h after administration of
DDP.
Cisplatin (DDP) is one of the most effective chemothera-
peutic agents in the treatment of ovarian, testicular and head
and neck cancers. Unfortunately, these tumours characteris-
tically develop resistance to DDP, and this contributes to
treatment failure (Andrews & Howell, 1990; Timmer-Bosscha
et al., 1992). Early detection of intrinsic resistance could
allow for treatment changes that would be beneficial to the
patient, for example the immediate addition of radiation
therapy to a chemotherapy programme. However, in most
cases, it is impossible to detect the presence ofresistance until
weeks after the chemotherapeutic treatment when the tumour
is found not to have decreased in size, or even continued to
increase in volume.
Two recent developments hold out promise for the
development of a molecular strategy potentially capable of
providing information on the extent of tumour injury within
24 h of the initiation of treatment. First is the recent
identification and cloning of a large number of DNA
damage-inducible genes whose transcription is activated by
cellular injury (reviewed by Holbrook & Fornace, 1991).
Second is the development of polymerase chain reaction
(PCR)-based methodology for accurately quantifying the
level of expression of specific messages in very small numbers
of cells (Horikoshi et al., 1992; Los et al., 1993a). Among the
damage-inducible genes, GADD153 is ofparticular interest as
a candidate for early detection of tumour injury because it is
induced to high levels by a large number of agents that cause
either DNA damage or cell cycle arrest. These include UV
light, hypoxia, serum starvation, medium depletion, cysteine
conjugates, dithiothreitol and various chemotherapeutic
drugs (Fornace et al., 1989; Chen et al., 1992; Luethy &
Holbrook, 1992; Price & Calderwood, 1992). In addition, the
induction is transient which, in principle, might permit
repeated assessment of the magnitude of its induction with
serial courses of treatment.
GADD153 was originally cloned by hybridisation subtrac-
tion of mRNA from proliferating vs UV-treated CHO cells
(Fornace et al., 1988). It is one of a family of genes that is
coordinately regulated by agents that induce growth arrest or
DNA damage (Fornace et al., 1989). GADD153 is highly
conserved in mammalian species; hamster GADD153 shares
78% nucleotide sequence identity with the human gene (Park
et al., 1992) and >85% with the mouse gene (Ron &
Habener, 1992). Although the function of GADD153 in the
damage response is unknown, it appears to be a modulator
of the transcription factors C/EBP and LAP (Ron &
Habener, 1992). Ron and Habener cloned CHOP-10, the
mouse homologue of GADDJ53, by identifying proteins that
could dimerise with CCAAT/enhancer-binding protein (C/
EBP) or liver-enriched transcriptional activator protein
(LAP), but not bind to the cytokine-responsive enhancer
element APRE (acute-phase responsive element). They found
that CHOP-10 localised in the nucleus and co-
immunoprecipitated with LAP. They also found that overex-
pression of CHOP-10 inhibited the activation of an APRE-
driven luciferase construct.
Recently, the same group has reported that GADDJ53 is
involved in the oncogenesis of human myxoid liposarcomas
(Aman et al., 1992; Crozat et al., 1993). They demonstrated
that the characteristic chromosomal translocation found in
this tumour type creates a fusion protein of GADDJ53 and a
previously unreported RNA-binding protein (named TLS for
translocated in liposarcoma; Crozat et al., 1993). This fusion
protein contains the DNA-binding and leucine zipper
domains of the GADD153 protein fused to a domain in TLS
that has a glycine-rich region similar to that of the transcrip-
tion factor SP-1. They hypothesise that this translocation
changes the effect of GADD153/CHOP-10 from a transcrip-
tional suppressor to a oncogenic transcriptional activator.
We report here studies that demonstrate that the mag-
nitude of the increase in GADDJ53 messenger RNA can be
used to detect and quantify the amount of tumour cell injury
produced by DDP within 24 h of drug exposure both in vitro
and in vivo, and that there is a good correlation between
GADDJ53 mRNA induction and the extent of cell kill in
vitro.
Materials and methods
Cell culture and conditions
The human ovarian serous adenocarcinoma cell line 2008
(DiSaia et al., 1972) was grown as a monolayer culture in a
humidified incubator at 37°C and 5% carbon dioxide. 2008
cells were maintained in complete RPMI-1640 supplemented
with 5% fetal calf serum and 2 mm glutamine. Cisplatin was
obtained from Bristol laboratories (Princeton, NJ, USA).
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Northern blotting
Total cellular RNA was extracted by the guanidium
isothiocyanate (GITC)-caesium chloride method (Davis et
al., 1986). The RNA was separated on 1% formaldehyde
agarose gels and transferred to MagnaGraph nylon mem-
branes (MSI, Westboro, MA, USA) by capillary transfer.
The RNA was immobilised by baking at 80°C for 30 min.
Probes were labelled with [32P]dCTP using the Amersham
Multiprime kit (Amersham, Arlington Heights, IL, USA).
The blots were prehybridised, hybridised and washed as des-
cribed in Maniatis et al. (Sambrook et al., 1989). The blots
were exposed to film (Fuji, RX-50 X-ray film) and quan-
titated either by laser densitometry (LKB Ultroscan XL,
Bromma, Sweden) or by the Molecular Imager System (Bio-
Rad, Hercules, CA, USA). The human GADD153 probe was
a gift from Dr N.J. Holbrook (NIA, NIH, Baltimore, MD,
USA). Lane loading differences were corrected for by com-
parison to the same blot hybridised with a P-actin probe.
In vivo experiments
Five million 2008 cells were injected subcutaneously above
the foreshoulder of female nu/nu mice (Harlan, Sprague-
Dawley, Indianopolis, IL, USA). The xenografts were
allowed to grow to a volume of approximate 1 ml. At that
time, the mice were treated intraperitoneally with DDP. The
mice were sacrificed and the tumours were removed at the
appropriate time point. The tumours were homogenised
using a Polytron homogenizer (Biospec Products, Bartlesville,
OK, USA) in GITC buffer. RNA was extracted as described
above.
Results
Dose dependence ofthe increase in GADD153 mRNA levels
after DDP treatment in vitro
In order to determine whether DDP increased GADD153
mRNA levels in exponentially growing human ovarian car-
cinoma 2008 cells, cultures were treated with 5, 10, 20 or
30,UM DDP for 1 h and then returned to drug-free medium..
RNA extracted at 24 h after DDP treatment was subjected to
Northern analysis. Figure 1 shows that GADD153 mRNA
expression was increased by DDP treatment, and that this
increase was approximately linear with DDP concentration
up to 30tLM. A representative blot is shown in Figure la; the
quantitation of the autoradiogram is shown graphically in
Figure lb.
Time course ofthe increase in GADD153 mRNA levels after
DDP treatment in vitro
Figure 2 shows the time course of the increase in GADD153
mRNA levels after DDP treatment in 2008 cells growing in
vitro. The cells were treated with 20 1AM DDP for 1 h and
RNA was extracted at 8, 24, 48, 96 and 120 h after DDP
exposure. An increase in GADD153 mRNA level was evident
at 8 h; this increase had peaked at 24 h, and had returned to
basal levels by 120 h when the cells had returned to exponen-
tial growth.
Effect ofDDP exposure schedule on GADD153 mRNA levels
in vitro
In order to determine whether the increase in GADD153
mRNA caused by DDP was dependent on the schedule of
drug exposure, GADD153 mRNA levels were measured in
cells treated with equitoxic exposures using two different
DDP regimens. In the 2008 ovarian carcinoma cell line the
IC50 for a 24 h exposure to DDP is 10-fold less than the IC50
for a 1 h exposure (data not shown). A 1 h treatment with
SI M DDP and a 24 h treatment with 0.5gM DDP both
resulted in inhibition of colony formation by 50%. As shown
in Figure 3, such equitoxic doses of DDP resulted in approx-
imately equal increases of GADD153 mRNA measured at
24 h after the start ofdrug exposure. This indicates that, over
the range studied, the schedule of drug exposure had little
effect on the magnitude of the injury response.
Dose dependence ofthe increase in GADD153 mRNA levels
after DDP treatment in vivo
The ability of DDP to increase GADDI53 mRNA levels in
vivo was investigated in 2008 xenografts growing sub-
cutaneously in nude mice. Implanted cells were allowed to
a
0 0 10 10 20 20 30 30
GADD153
P-Actin
z
E
C) C)
0 C *0
Ur-
CD
sD
Ul
b
DDP concentration (pM)
Figure 1 The effect of DDP on GADDJ53 message levels.
Exponentially growing 2008 cells were treated with DDP for I h
and returned to drug-free medium for 24 h. GADD153 mRNA
induction was assayed by Northern blot analysis. a, A represen-
tative Northern blot. b, The hybridisation has been quantitated
and is shown graphically. Lane loading is corrected by ratio to
P-actin and values are relative to untreated control cells. Error
bars ± s.e.m.
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Figure 2 The effect of post-treatment time on GADD153 mes-
sage levels after a 1 h exposure to 20 1M DDP. Exponentially
growing 2008 cells were treated with 20gM DDP for 1 h and
returned to drug-free medium for 8, 24, 48, 96 and 120 h.
GADD153 mRNA levels were assayed by Northern blot analysis.
Values are corrected for P-actin and reported relative to untreated
control cells. Error bars ± s.e.m.
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grow into a tumour with a volume of approximately 1 ml,
and then the mice were treated with 15, 30, 50 or
100mgkg-' DDP administered as a single intraperitoneal
injection. Figure 4 shows the results obtained when RNA
was harvested at 24 h after drug treatment and subjected to
Northern analysis. DDP increased GADD153 mRNA in the
2008 xenografts in a dose-dependent manner. The smallest
dose that produced a reproducibly measurable increase in
GADD153 message was 15mgkg-'. At a dose of 100mg
kg-', the fold induction of GADD153 message reached
7.2 ± 0.5 (s.e.m.).
Time course ofthe increase in GADD153 mRNA levels after
DDP treatment in vivo
The time course of the increase in GADD153 mRNA was
investigated in 2008 xenografts in nude mice following
administration of DDP at a dose of 30 mgkg-1 by the
intraperitoneal route. Increased levels of GADD153 mRNA
were detectable at 24h, were maximal at 48h and had
returned toward baseline by 72 h following DDP treatment
(Figure 5). Therefore, as was found in vitro, the increase in
GADD153 mRNA levels was transient in vivo and levels
returned toward baseline sufficiently rapidly that one
would expect the DDP-induced transcriptional activation of
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GADD153 to have resolved prior to the next dose of
chemotherapy even if given on a weekly schedule.
Heterogeneity ofGADD153 mRNA levels after DDP
treatment in vivo
In order to use the magnitude of increase in GADD153
mRNA as a surrogate for clinical tumour regression, the
coefficient of variation between biopsies must be relatively
small. Variations in the increase of GADD153 mRNA levels
produced by equal doses of DDP in separate tumours were
studied in the in vivo model. Northern analysis of 2008
xenografts using RNA harvested 24 h following a single
intraperitoneal dose of DDP 30 mg kg- demonstrated a 3.2-,
4.0-, 3.9- and 3.6-fold increase in GADD153 mRNA in four
tumours, which yielded a mean ± s.d. of 3.7 ± 0.4 and a
coefficient of variation of 11.7%.
Increase in GADD153 mRNA levelsproduced by DDP
treatment in melanoma and head and neck cancer xenografts
The ability of DDP to increase GADD153 mRNA levels in
vivo was investigated in two additional xenografts, T289
human melanoma and UMSCC lOb human squamous cell
carcinoma, growing subcutaneously in nude mice. Implanted
cells were allowed to grow into a tumour with a volume of
approximately I ml, and then mice were treated with
50 mg kg-' DDP administered as a single intraperitoneal
injection. RNA from the tumours was extracted 24h later
and analysed by Northern blot. Table 1 shows that DDP
increases the levels of GADD153 mRNA in a variety of
human tumour xenografts of different types.
Discussion
A large number of genes that are induced by DNA damage
have now been identified. We hypothesised that the mag-
nitude of induction of one or more of these could provide a
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Figure 3 The effect of equitoxic DDP treatments on the induc-
tion of GADDJ53 mRNA. Exponentially growing 2008 cells were
treated with IC50, ICg, or ICg9 exposures of DDP using either a
1 h (U) or a 24 h (0) duration of treatment. GADDJ53 mRNA
levels were assayed by Northern blot analysis 24 h after the start
of DDP exposure. Values are corrected for P-actin and reported
relative to untreated control cells. Error bars ± s.e.m.
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Figure 4 The effect of intraperitoneal DDP on GADDJ53 mes-
sage levels in 2008 xenografts in nude mice. Mice bearing 2008
xenografts were treated with DDP, RNA was harvested 24 h later
and GADD153 mRNA levels were assayed by Northern blot
analysis. Values are corrected for P-actin and are reported relative
to tumours from untreated animals. Error bars ± s.e.m.
Figure 5 The effect of post-treatment time on GADD153 mes-
sage levels in 2008 xenografts in nude mice. Mice bearing 2008
xenografts were treated with 30mgkg-' DDP, and RNA was
harvested 24, 48 or 72 h later. GADD153 mRNA levels were
assayed by Northern blot analysis. Values are corrected for P-
actin and are reported relative to tumours from untreated
animals. Error bars ± s.e.m.
Table I Increase in GADD153 mRNA in human tumour xenografts
following 50 mg kg-' DDP
Fold GADD153 mRNA
Cell line Tumour type increase ± s.e.m.
2008 Ovarian carcinoma 5.1 ± 1.3
T289 Melanoma 8.1 ± 0.6
UMSCC 10b Squamous cell carcinoma 3.0 0.4INDUCTION OF GADD153 BY CISPLATIN 1105
molecular approach to the long-standing clinical problem of
how to rapidly determine whether a tumour is destined to
respond to treatment that has recently been administered.
Among the gadd family of genes, GADD153 has a number of
traits that make it a strong candidate for this role of sur-
rogate marker. First, GADD153 has low basal expression
such that even relatively small degrees of induction can be
detected. Second, unlike many of the other damage-inducible
genes, it is not highly induced by treatment of the cells with
phorbol ester tumour promoters (Holbrook & Fornace,
1991), and, by inference, may be less susceptible to induction
by environmental factors. Third, GADD153 is not cell cycle
regulated. If tumour injury was monitored with a gene whose
transcription was activated by both injury and an increase in
growth rate, such as c-fos or c-jun, then it might be difficult
to distinguish between impending response and the increase
in the growth fraction that often accompanies partially suc-
cessful chemotherapy. Finally, the increase in GADD153
mRNA is an event that is quite far downstream in the
sequence of steps that lead from administration of chemo-
therapy to tumour cell death. The magnitude of this increase
reflects the net effect of several factors, including the amount
of drug given to the patient, the total plasma exposure, how
much of the drug actually got into the tumour cell, how
much found its critical target within the cell, and how
effectively cellular defence mechanisms offset the action of
the drug. Thus, in principle, it reflects the extent to which the
tumour has been injured. One can reasonably expect that this
will be much more tightly linked to clinical response than
post-treatment measurements such as plasma drug concentra-
tion or even total tumour drug level.
The expression of a number of genes, including HSP60
(Kimura et al., 1993) and ERCCI (Dabholkar et al., 1992),
has been postulated to be predictive of how well a tumour
will respond to DDP. The pretreatment measurement of
these genes can detect intrinsic resistance or differences in
DNA repair capability. Since GADD153 is measured after
DDP treatment, the increase in mRNA levels reflects tumour
damage and may give different information from pretreat-
ment measurement of HSP60 or ERCCI. At present a com-
parison of the correlation between the levels of these genes
and the clinical outcome of the treatment has not been
undertaken. It is important to point out that the level of
GADD153 mRNA expression at 24 h post treatment is likely
to be a complex function of both the amount of damage
done to DNA and the ability of the cell to repair this
damage.
In approaching the use of GADD153 as a potential
molecular marker of injury, we chose to focus on a single
widely used chemotherapeutic agent, DDP, and a type of
tumour, ovarian carcinoma, that initially responds well to
DDP treatment but for which acquired resistance usually
becomes a major clinical problem (Andrews et al., 1990;
Perez et al., 1991). Using the human ovarian carcinoma cell
line 2008, the results indicate that GADD153 can be induced
12-fold by levels of drug that result in approximately 10%
survival of the original population of cells. The magnitude of
the induction was predictably dependent on the extent of
tumour cell kill, and it was relatively independent of the
schedule of drug administration (i.e. 1 vs 24 h exposure). In
addition, we confirmed that the time course of induction and
return of mRNA levels to their basal level was such that it
would be appropriate to use GADD153 induction as a
measure of injury on serial courses of treatment spaced more
than a week or so apart. The time course results that we
obtained with the human 2008 cells exposed to DDP differ
considerably from the induction of GADD153 by methyl
methanesulphonate (MMS) in CHO cells. In the latter system
Fornace et al. (1989) reported that induction was maximal at
the end of a 4 h exposure to drug. At the present time no
other explanations for these differences are available save for
the fundamental differences in cellular system and drug
tested. For example, MMS forms monoadducts with DNA
(Friedberg, 1985), DDP forms both mono- and biadducts
with DNA (Pinto & Lippard, 1985). These different types of
adducts may have different detection and repair systems that
could account for the differences in induction time.
Importantly, the results obtained in this study indicate that
GADD153 mRNA was increased in vivo in xenografts of
several different types by doses of DDP that are clinically
relevant, and that the time course of induction parallels that
observed in vitro. In patients, DDP is commonly admini-
stered to cancer patients at doses of 90-100mgm-2, and
some clinical trials are experimenting with doses as high as
150mg m2 (Los et al., 1993b). Los et al. (1994) have shown
that in patients with head and neck tumours who show a
complete response to DDP, GADD153 mRNA levels have
increased an average of 3.25-fold. Although the LDIO for
DDP in nude mice is 15 mgkg-' (unpublished data), using
the empirically derived conversion formulas of Freireich et al.
(1966), a DDP dose of 30mgkg-' in the mouse can be
expected to generate the same degree of toxicity as a dose of
92 mg m-2 in a human. Thus, our data suggest that the
magnitude of induction of GADD153 by doses commonly
used in the clinic will be sufficient to permit its use as a
measure of the extent to which a tumour believes it has been
injured 24 h after initiation of therapy.
The ability to increase GADD153 mRNA to high levels by
doses ofdrug that are sufficient to cause tumour regression is
only the first step in developing a strategy for rapid assess-
ment of tumour injury. Given the heterogeneous nature of
many tumours, how reliable would any one measurement of
GADD153 expression be in a single biopsy from a given
tumour? Comparing a small number of 2008 xenografts, we
found a coefficient of variation of only 11.7%, suggesting
that within this type of tumour, measurement of GADD153
mRNA may be associated with an acceptably small variance.
However, GADD153 mRNA levels from multiple biopsies of
single tumours will have to be extensively studied in order to
ensure that the variation is small in heterogeneous tumour
cell populations from patients.
The prospect of translating the use of GADD153 induction
into a clinically useful tool has been much improved by
development of PCR-based technologies that permit quan-
titative measurement of mRNA levels in as few as 1,000 cells
(Los et al., 1993a). Sufficient cellular material can be
obtained from a single fine needle aspiration biopsy to permit
accurate quantification of GADD153 mRNA level before and
again 24 h after treatment (Los et al., 1994). Additional
studies are needed to determine the variance associated with
measurements made on needle biopsies obtained from
different sections of the same tumour as well as from the
same tumour before and after treatment. Also, further
validation of the assay will be needed to confirm that there is
a good correlation between the magnitude of GADD153
induction and the clinical response of the tumour. It is
important to point out that changes in the magnitude of
induction of GADD153 during serial courses of the same
therapy may provide a method for detection of drug resis-
tance at a time well before it becomes clinically apparent.
In this study we focused on GADD153 induction by the
chemotherapeutic agent DDP. However, since GADD153 can
be induced by a large number of chemotherapeutic agents as
well as ultraviolet radiation (Luethy & Holbrook, 1992; D.P.
Gately, unpublished data), it may be possible to use the
induction of this gene to monitor the extent of tumour injury
produced by many modalities of treatment.
Abbreviations: DDP, cisplatin; gadd, growth arrest and DNA
damage; IC50, concentration of drug required to inhibit colony for-
mation by 50%; GITC, guanidine isothiocyanate; CHO, Chinese
hamster ovary; C/EBP, CCAAT/enhancer-binding protein; LAP,
liver-enriched transcriptional activator protein; APRE, acute-phase
response element.
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